Advancing RAS inhibition:broad-spectrum targeting and tumor-selective activity of RMC-7977 in cancer therapy  

作　　者：Qunli Xiong Yaguang Zhang 

机构地区：[1]Laboratory of Gastrointestinal Tumor Epigenetics and Genomics,Frontiers Science Center for Disease-related Molecular Network,West China Hospital,Sichuan University,Chengdu 610041,China [2]Abdominal Oncology Ward,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Science China(Life Sciences)》2025年第2期586-587,共2页中国科学(生命科学英文版)

基　　金：supported by the National Natural Science Foundation of China(82203447);the Natural Science Foundation of Sichuan,China(2022NSFSC1424);the Postdoctoral Research Project,West China Hospital,Sichuan University(18HXBH068)。

摘　　要：In cancer,the proto-oncogene RAS frequently mutates at codons 12,13,and 61,with these mutations propelling tumor progression by locking RAS proteins in their active,GTP-bound state(Pylayeva-Gupta et al.,2011;Yang et al.,2023).Despite the recent approval of small molecule inhibitors targeting KRAS(G12C)for non-small cell lung cancer(de Langen et al.,2023),a broadspectrum small molecule inhibitors for multiple RAS mutations have remained elusive.

关 键 词：cancer LUNG 

分 类 号：R730.5[医药卫生—肿瘤]